The therapeutic effect of levosimendan in patients with prolonged ventilator weaning and cardiac dysfunction

• Published in: Journal of international medical research 2024-07, Vol.52 (7), p.3000605241263166
• Main Authors: Xiong, Fang, Hu, Zongjun, Liu, Chao, Zhang, Kexiang, Zhou, Qilong, Chen, Jianguo, Lu, Hua, Yue, Xi, Zhao, Jianxin, Pan, Pengfei
• Format: Article
• Language: English
• Subjects: Aged; Cardiotonic Agents - therapeutic use; Female; Heart Diseases - drug therapy; Heart Diseases - physiopathology; Humans; Male; Middle Aged; Pyridazines - therapeutic use; Respiration, Artificial; Retrospective Studies; Simendan - therapeutic use; Treatment Outcome; Ventilator Weaning - methods; Ventilators; Weaning
• ISSN: 0300-0605; 1473-2300; 1473-2300
• DOI: 10.1177/03000605241263166

Objective To explore the therapeutic effect of levosimendan in patients with prolonged ventilator weaning and cardiac dysfunction. Method Patients with prolonged ventilator weaning and cardiac dysfunction were randomly allocated to receive conventional treatment (control group) or intravenous infusion of levosimendan for 24 h based on conventional treatment (levosimendan group). Weaning success rates were then compared between the two groups. The study was retrospectively registered with Research Registry (ID No. researchregistry10304). Results A total of 40 patients were included (20 per group). Within 3 days after initiation of treatment, significantly more cases were successfully weaned in the levosimendan group versus control group (eight versus four cases, respectively). Among the eight patients who underwent pulse indicator continuous cardiac output monitoring in the levosimendan group, the global ejection fraction increased 24 h after treatment, and the cardiac function index and cardiac index increased 72 h after treatment. Conclusion For patients requiring prolonged mechanical ventilation who have concomitant cardiac dysfunction, levosimendan may be considered to increase the probability of weaning success.